Compare CPS & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPS | MRVI |
|---|---|---|
| Founded | 1960 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 631.2M | 472.8M |
| IPO Year | 2005 | 2020 |
| Metric | CPS | MRVI |
|---|---|---|
| Price | $32.14 | $3.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $43.33 | $4.57 |
| AVG Volume (30 Days) | 263.5K | ★ 1.1M |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.87 | 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | $4.42 | $11.80 |
| Revenue Next Year | $6.36 | $7.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.38 | $1.67 |
| 52 Week High | $47.98 | $4.11 |
| Indicator | CPS | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 38.49 | 52.07 |
| Support Level | $30.64 | $3.25 |
| Resistance Level | $35.13 | $3.65 |
| Average True Range (ATR) | 1.43 | 0.19 |
| MACD | -1.03 | 0.04 |
| Stochastic Oscillator | 16.55 | 58.74 |
Cooper-Standard Holdings Inc is engaged in the manufacture of sealing and fluid handling systems (consisting of fuel and brake delivery systems and fluid transfer systems). Its products are designed for passenger vehicles and light trucks that are manufactured by automotive original equipment manufacturers (OEMs) and replacement markets. It has two reportable segments: Sealing Systems and Fluid Handling Systems. The group's geographic regions are North America, Europe, Asia Pacific, and South America.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.